At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 26 enrolled
Drug / intervention
Cefprozil for oral suspension 250 mg/5 mL +1 moredrug
Likely dose
Cefprozil for oral suspension 250 mg/5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Relative Bioavailability Study of Cefprozil for Oral Suspension 250 mg/5 mL Under Fasting Conditions
In Brief
A Phase 1 clinical trial evaluating Cefprozil for oral suspension 250 mg/5 mL and CEFZIL® for Oral Suspension 250 mg/5mL for Healthy. Completed, enrolled 26 participants across 2 sites.
Detailed Summary
The objective of this study is to compare the relative bioavailability of cefprozil for oral suspension 250 mg/5 mL (TEVA Pharmaceuticals USA) with that of CEFZIL® for Oral Suspension 250 mg/5 mL (Bristol-Myers Squibb) in healthy, non-smoking adults under fasting conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2004
Primary CompletionApr 2004
First PostedFeb 2009
TodayJul 2026
First PostedFeb 3, 2009
Enrollment StartApr 1, 2004
Primary CompletionApr 1, 2004
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.4 years ago
Interventions
Cefprozil for oral suspension 250 mg/5 mLdrug
1 x 250 mg/5 mL, single-dose fasting
CEFZIL® for Oral Suspension 250 mg/5mLdrug
1 x 250 mg/5 mL, single-dose fasting